Seok Jong Chung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/519779/publications.pdf

Version: 2024-02-01

331670 477307 1,513 106 21 29 citations h-index g-index papers 111 111 111 1837 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 129-136.	2.8	3
2	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease. Journal of Neurology, 2022, 269, 2948-2960.	3.6	3
3	Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations. Nature Communications, 2022, 13, 519.	12.8	15
4	Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease. Neurology, 2022, 98, .	1.1	8
5	Association of Alzheimer's Disease with COVID-19 Susceptibility and Severe Complications: A Nationwide Cohort Study. Journal of Alzheimer's Disease, 2022, 87, 701-710.	2.6	13
6	Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naÃ-ve Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 1-7.	2.2	7
7	Accuracy of Machine Learning Using the Montreal Cognitive Assessment for the Diagnosis of Cognitive Impairment in Parkinson's Disease. Journal of Movement Disorders, 2022, 15, 132-139.	1.3	1
8	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. Nutrition, 2021, 83, 111090.	2.4	36
9	The pattern of FP-CIT PET in pure white matter hyperintensities–related vascular parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 1-6.	2.2	2
10	Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 239-249.	2.8	2
11	Inosine 5'â€Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVEâ€MSA) Tj ETÇ	2q1 1 0.78 -	4314 rgBT /C
12	Interaction of CSF αâ€synuclein and amyloid beta in cognition and cortical atrophy. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12177.	2.4	5
13	White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 1411-1419.	3.9	22
14	Donepezil for mild cognitive impairment in Parkinson's disease. Scientific Reports, 2021, 11, 4734.	3.3	10
15	Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes. Journal of Alzheimer's Disease, 2021, 79, 1471-1487.	2.6	2
16	Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinsonâ∈™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2242-2248.	3.6	5
17	Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease. Neurology, 2021, 96, e2121-e2131.	1.1	32
18	Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease. Brain, 2021, 144, 1127-1137.	7.6	30

#	Article	IF	Citations
19	Structural connectivity networks in Alzheimer's disease and Lewy body disease. Brain and Behavior, 2021, 11, e02112.	2.2	4
20	Different patterns of \hat{l}^2 -amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. Neurobiology of Aging, 2021, 101, 199-206.	3.1	2
21	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease. Journal of Neurology, 2021, 268, 4203-4212.	3.6	8
22	Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-NaÃ⁻ve Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 1-10.	2.8	9
23	Estimates of Long-Term Care Utilization and Lifetime Distribution of Medical Cost for Dementia in Korea. Korean Journal of Clinical Geriatrics, 2021, 22, 22-33.	0.1	0
24	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. Scientific Reports, 2021, 11, 14394.	3.3	7
25	Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 1715-1724.	2.8	6
26	Effects of statins on dopamine loss and prognosis in Parkinson's disease. Brain, 2021, 144, 3191-3200.	7.6	22
27	Postganglionic Sudomotor Dysfunction and Brain Glucose Hypometabolism in Patients with Multiple System Atrophy. Journal of Parkinson's Disease, 2021, 11, 1247-1256.	2.8	2
28	Diffusion tensor imagingâ€based pontine damage as a degeneration marker in synucleinopathy. Journal of Neuroscience Research, 2021, 99, 2922-2931.	2.9	1
29	Neural correlates of selfâ€awareness of cognitive deficits in nonâ€demented patients with Parkinson's disease. European Journal of Neurology, 2021, 28, 4022-4030.	3.3	3
30	Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. Neurobiology of Aging, 2021, 106, 45-54.	3.1	9
31	Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. Stem Cells International, 2021, 2021, 1-10.	2.5	5
32	Effects of Alzheimer's disease and Lewy body disease on subcortical atrophy. European Journal of Neurology, 2020, 27, 318-326.	3.3	9
33	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. Neurobiology of Aging, 2020, 87, 11-17.	3.1	15
34	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 873-885.	2.6	4
35	Dysautonomia Is Linked to Striatal Dopamine Deficits and Regional Cerebral Perfusion in Early Parkinson Disease. Clinical Nuclear Medicine, 2020, 45, e342-e348.	1.3	10
36	Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. Clinical Nuclear Medicine, 2020, 45, e463-e468.	1.3	9

#	Article	IF	Citations
37	Factor analysis–derived cognitive profile predicting early dementia conversion in PD. Neurology, 2020, 95, e1650-e1659.	1.1	21
38	The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism. Brain and Behavior, 2020, 10, e01808.	2.2	9
39	Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. Parkinsonism and Related Disorders, 2020, 81, 140-143.	2.2	6
40	Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease. Movement Disorders, 2020, 35, 2240-2249.	3.9	17
41	Effects of APOE4 on Alzheimer's disease, Lewy body disease, cerebral amyloid deposition and cognitive dysfunction. Alzheimer's and Dementia, 2020, 16, e037300.	0.8	0
42	Gender-specific effect of urate on white matter integrity in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 75, 41-47.	2.2	7
43	Clinical and striatal dopamine transporter predictors of \hat{l}^2 -amyloid in dementia with Lewy bodies. Neurology, 2020, 94, e1344-e1352.	1.1	17
44	Urate is closely linked to white matter integrity in multiple system atrophy. Annals of Clinical and Translational Neurology, 2020, 7, 1029-1039.	3.7	4
45	Patterns of striatal dopamine depletion in early Parkinson disease. Neurology, 2020, 95, e280-e290.	1.1	25
46	White matter hyperintensities and risk of levodopaâ€induced dyskinesia in Parkinson's disease. Annals of Clinical and Translational Neurology, 2020, 7, 229-238.	3.7	16
47	Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease. Movement Disorders, 2020, 35, 577-586.	3.9	36
48	Cognitive anosognosia is associated with frontal dysfunction and lower depression in Parkinson's disease. European Journal of Neurology, 2020, 27, 951-958.	3.3	10
49	Dopaminergic Depletion, βâ€Amyloid Burden, and Cognition in Lewy Body Disease. Annals of Neurology, 2020, 87, 739-750.	5.3	27
50	Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia. Neurobiology of Aging, 2020, 89, 63-70.	3.1	24
51	Sexâ€dependent association of urate on the patterns of striatal dopamine depletion in Parkinson's disease. European Journal of Neurology, 2020, 27, 773-778.	3.3	9
52	Impaired functional connectivity of sensorimotor network predicts recovery in drug-induced parkinsonism. Parkinsonism and Related Disorders, 2020, 74, 16-21.	2.2	5
53	Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson's disease. Scientific Reports, 2020, 10, 5567.	3.3	7
54	Initial motor reserve and long-term prognosis in Parkinson's disease. Neurobiology of Aging, 2020, 92, 1-6.	3.1	15

#	Article	IF	Citations
55	Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson's Disease. Journal of Movement Disorders, 2020, 13, 133-141.	1.3	22
56	Emerging Concepts of Motor Reserve in Parkinson's Disease. Journal of Movement Disorders, 2020, 13, 171-184.	1.3	30
57	Structural and Resting-State Brain Alterations in Trauma-Exposed Firefighters: Preliminary Results. Journal of the Korean Society of Radiology, 2020, 81, 676.	0.2	2
58	Sexâ€specific association of urate and levodopaâ€induced dyskinesia in Parkinson's disease. European Journal of Neurology, 2020, 27, 1948-1956.	3.3	5
59	A Case of Abnormal Postures in the Left Extremities after Pontine Hemorrhage: Dystonia or Pseudodystonia?. Journal of Movement Disorders, 2020, 13, 62-65.	1.3	2
60	Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1541-1549.	2.8	4
61	White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 105-109.	2.2	27
62	Magnetic Resonance Imaging–Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease. Movement Disorders, 2019, 34, 1672-1679.	3.9	60
63	Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naÃ⁻ve postmenopausal Parkinson's disease. Scientific Reports, 2019, 9, 10531.	3.3	35
64	Cerebellar connectivity in Parkinson's disease with levodopaâ€induced dyskinesia. Annals of Clinical and Translational Neurology, 2019, 6, 2251-2260.	3.7	15
65	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. Human Brain Mapping, 2019, 40, 3784-3794.	3.6	41
66	Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinson's disease. Journal of Neurology, 2019, 266, 1601-1610.	3.6	17
67	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1652-1660.	6.4	11
68	Mild cognitive impairment reverters have a favorable cognitive prognosis and cortical integrity in Parkinson's disease. Neurobiology of Aging, 2019, 78, 168-177.	3.1	16
69	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. Neurology, 2019, 92, e2015-e2026.	1.1	28
70	Dysautonomia is associated with structural and functional alterations in Parkinson disease. Neurology, 2019, 92, e1456-e1467.	1.1	21
71	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. Neurology, 2019, 92, e1468-e1478.	1.1	16
72	Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?. Journal of Parkinson's Disease, 2019, 9, 241-247.	2.8	9

#	Article	IF	Citations
73	P4â€572: NEURAL CORRELATES OF COGNITIVE PERFORMANCE IN ALZHEIMER'S DISEASE AND LEWY BODY DISEASE SPECTRA. Alzheimer's and Dementia, 2019, 15, P1538.	0.8	0
74	P4â€571: DISTINCT FPâ€CIT PET PATTERNS OF ALZHEIMER'S DISEASE WITH PARKINSONISM AND DEMENTIA WILLEWY BODIES. Alzheimer's and Dementia, 2019, 15, P1538.	TH _{0.8}	0
75	Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 54-59.	2.2	20
76	Clinical relevance of amnestic versus nonâ€amnestic mild cognitive impairment subtyping in Parkinson's disease. European Journal of Neurology, 2019, 26, 766-773.	3.3	25
77	Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease. Movement Disorders, 2019, 34, 299-301.	3.9	1
78	Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. Journal of Movement Disorders, 2019, 12, 113-119.	1.3	26
79	The Influence of Body Mass Index at Diagnosis on Cognitive Decline in Parkinson's Disease. Journal of		

#	Article	IF	CITATIONS
91	Volumetric analysis of the cerebellum in patients with progressive supranuclear palsy. European Journal of Neurology, 2017, 24, 212-218.	3.3	4
92	Does smoking impact dopamine neuronal loss in de novo Parkinson disease?. Annals of Neurology, 2017, 82, 850-854.	5. 3	15
93	Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinson's Disease. Sleep, 2017, 40, .	1.1	15
94	Rapid eye movement sleep behaviour disorder and striatal dopamine depletion in patients with Parkinson's disease. European Journal of Neurology, 2017, 24, 1314-1319.	3.3	26
95	The Computerized Table Setting Test for Detecting Unilateral Neglect. PLoS ONE, 2016, 11, e0147030.	2.5	5
96	Patterns of Neuropsychological Profile and Cortical Thinning in Parkinson's Disease with Punding. PLoS ONE, 2015, 10, e0134468.	2.5	20
97	Cerebral Microbleeds in Patients with Dementia with Lewy Bodies and Parkinson Disease Dementia. American Journal of Neuroradiology, 2015, 36, 1642-1647.	2.4	28
98	Positional Suppression of Periodic Alternating Nystagmus. Journal of Neuro-Ophthalmology, 2014, 34, 162-164.	0.8	2
99	Subcortical vascular dementia (SVaD) without hypertension (HTN) may be a unique subtype of vascular dementia (VaD). Archives of Gerontology and Geriatrics, 2014, 58, 231-235.	3.0	3
100	Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson's disease. Neurobiology of Aging, 2014, 35, 1739-1743.	3.1	44
101	Predictive value of the smell identification test for nigrostriatal dopaminergic depletion in Korean tremor patients. Parkinsonism and Related Disorders, 2013, 19, 1018-1021.	2.2	4
102	Callosal dysarthria. Clinical Neurology and Neurosurgery, 2013, 115, 1173-1176.	1.4	5
103	Effect of APOE genotype on gray matter density in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 138-140.	2.2	1
104	Dental implantsâ€induced taskâ€specific oromandibular dystonia. European Journal of Neurology, 2013, 20, e80.	3.3	6
105	Neuroanatomical Heterogeneity of Essential Tremor According to Propranolol Response. PLoS ONE, 2013, 8, e84054.	2.5	17
106	A Case of Isolated Middle Cerebral Artery Stenosis with Hemichorea and Moyamoya Pattern Collateralization. Journal of Movement Disorders, 2013, 6, 13-16.	1.3	5